Company / Depreciation & Amortization
TEVA PHARMACEUTICAL INDUSTRIES LTD Depreciation & Amortization History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$1.0B
FY2025
5-year range
$1.0B / $1.3B
FY2021-FY2025
Trend
-5.4%
vs FY2024
Sector context
#8 of 163
Health Care
What the data says
Among 163 Health Care companies, TEVA PHARMACEUTICAL INDUSTRIES LTD is in the bottom 5% for depreciation & amortization. Depreciation & Amortization has declined for 8 consecutive years, from $2.1B in FY2017 to $1.0B in FY2025.
Based on SEC 10-K filings.
$1.0B in FY2025 with a 5-year CAGR of -8.4%. Top quartile in the Health Care sector.
Improved from $1.2B to $1.0B over the past 2 years.
Health Care sector context is included.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- -8.5%
- 5-Year CAGR
- -8.4%
- 10-Year CAGR
- -
Sector benchmark
+356.7% above sector average
Key checks
Key Insights
- TEVA PHARMACEUTICAL INDUSTRIES LTD's depreciation & amortization has declined for 8 consecutive years.
- 5-year CAGR of -8.4%, indicating a declining trend.
- In FY2025, depreciation & amortization decreased 5.4% year-over-year.
- Ranks #8 out of 163 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.41 (distress zone, below 1.8 threshold)
- Negative profit margin: -9.9%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.0B | -5.4% |
| FY2024 | $1.1B | -8.2% |
| FY2023 | $1.2B | -11.9% |
| FY2022 | $1.3B | -1.7% |
| FY2021 | $1.3B | -14.6% |
| FY2020 | $1.6B | -9.6% |
| FY2019 | $1.7B | -6.5% |
| FY2018 | $1.8B | -12.8% |
| FY2017 | $2.1B | +38.6% |
| FY2016 | $1.5B | +16.5% |
As of FY2025 · SEC 10-K · Updated Mar 28, 2026